Sanofi (FRA:SNW)
Germany · Delayed Price · Currency is EUR 86.45
-0.19 (-0.22%)
At close: Oct 23, 2025
Sanofi Employees
Sanofi had 82,878 employees as of December 31, 2024. The number of employees decreased by 3,210 or -3.73% compared to the previous year.
Employees
82,878
Change (1Y)
-3,210
Growth (1Y)
-3.73%
Revenue / Employee
€551,871
Profits / Employee
€110,114
Market Cap
105.39B
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 82,878 | -3,210 | -3.73% |
| Dec 31, 2023 | 86,088 | -5,485 | -5.99% |
| Dec 31, 2022 | 91,573 | -3,869 | -4.05% |
| Dec 31, 2021 | 95,442 | -3,970 | -3.99% |
| Dec 31, 2020 | 99,412 | -997 | -0.99% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Siemens Aktiengesellschaft | 327,000 |
| Deutsche Telekom AG | 198,194 |
| Mercedes-Benz Group AG | 175,264 |
| Allianz SE | 156,626 |
| SAP SE | 109,121 |
| Siemens Energy AG | 98,000 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
| Siemens Healthineers AG | 72,000 |
Sanofi News
- 1 day ago - Sanofi Deepens Partnership with Medidata to Expedite the Development of New Therapies with an Improved Patient Journey - GlobeNewsWire
- 1 day ago - Sanofi Drug Shows Superior Efficacy In Genetic Disease Compared To Current Standard Therapy - Benzinga
- 2 days ago - Sanofi's Efdoralprin Alfa Meets All Endpoints In Phase 2 AATD Emphysema Study - Nasdaq
- 2 days ago - Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study - Benzinga
- 2 days ago - Press Release: Sanofi's efdoralprin alfa met all primary and key secondary endpoints in alpha-1 antitrypsin deficiency emphysema phase 2 study - GlobeNewsWire
- 3 days ago - Sanofi's Tzield gains faster review for additional diabetes indication from FDA - Seeking Alpha
- 3 days ago - Sanofi: FDA Accepts SBLA For Tzield For Expedited Review - Nasdaq
- 3 days ago - Press Release: Sanofi's Tzield accepted for expedited review in the US for stage 3 type 1 diabetes through FDA Commissioner's National Priority Voucher pilot program - Benzinga